2024
Vitamin B12 Supplementation in Psychiatric Practice
Kennedy K, Alexander J, Garakani A, Gross L, Mintz D, Parikh T, Pine J, Sumner C, Baron D. Vitamin B12 Supplementation in Psychiatric Practice. Current Psychiatry Reports 2024, 26: 265-272. PMID: 38696105, DOI: 10.1007/s11920-024-01505-4.Peer-Reviewed Original ResearchPsychiatric disordersB12 deficiencyB12 supplementationPsychiatric symptomsB12 levelsPharmacological treatment of psychiatric disordersTreatment of psychiatric disordersRisk factorsAssociated with neuropsychiatric symptomsSevere psychiatric presentationsManifestations of B12 deficiencyMild depressive symptomsVitamin B12 supplementationDepressive symptomsPsychiatric practicePsychiatric presentationsMedical workupNeuropsychiatric symptomsSymptoms of B12 deficiencyAugmentation strategiesPrevent depressionPharmacological treatmentCardinal symptomsDisordersSymptomsLifetime prevalence, comorbidities, and Sociodemographic predictors of post-traumatic stress disorder (PTSD): the National Epidemiology of Iranian Children and adolescents Psychiatric disorders (IRCAP)
Hooshyari Z, Mohammadi M, Salmanian M, Ahmadi N, Khaleghi A, Garakani A. Lifetime prevalence, comorbidities, and Sociodemographic predictors of post-traumatic stress disorder (PTSD): the National Epidemiology of Iranian Children and adolescents Psychiatric disorders (IRCAP). European Child & Adolescent Psychiatry 2024, 1-14. PMID: 38656607, DOI: 10.1007/s00787-024-02441-7.Peer-Reviewed Original ResearchPrevalence of post-traumatic stress disorderPost-traumatic stress disorderTraumatic eventsAnxiety disordersStress disorderPsychiatric disordersSchool-Age Children-Present and Lifetime VersionKiddie Schedule for Affective DisordersSchedule for Affective DisordersLifetime prevalenceLifetime prevalence of post-traumatic stress disorderType of traumatic eventPredictors of post-traumatic stress disorderRates of PTSDSeparation anxiety disorderGeneralized anxiety disorderK-SADS-PLOppositional defiant disorderPrevalence of PTSDRates of comorbidityAdolescent psychiatric disordersLifetime prevalence ratesPrevalence rates of comorbiditiesDepressive disorderLifetime Version
2022
An umbrella review on the use of antipsychotics in anxiety disorders: A registered report protocol
Garakani A, Freire RC, Buono FD, Thom RP, Larkin K, Funaro MC, Salehi M, Perez-Rodriguez MM. An umbrella review on the use of antipsychotics in anxiety disorders: A registered report protocol. PLOS ONE 2022, 17: e0269772. PMID: 35709149, PMCID: PMC9202921, DOI: 10.1371/journal.pone.0269772.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsSelective serotonin reuptake inhibitorsSerotonin-norepinephrine reuptake inhibitorsUse of antipsychoticsLong-term riskAnxiety disordersReuptake inhibitorsUmbrella reviewSide effectsPanic disorderSystematic reviewNon-antipsychotic medicationsUse of quetiapineFirst-line treatmentSerotonin reuptake inhibitorsNorepinephrine reuptake inhibitorsEvidence of efficacyCommon psychiatric disordersTraditional pharmacologic treatmentTreatment of anxietyAdjunctive treatmentPharmacologic treatmentTricyclic antidepressantsAntipsychoticsPsychiatric disordersSocial anxiety disorder
2020
Commentary on “A New Onset of Mania in a 49-Year-Old Man: An Interesting Case of Wilson Disease”
Garakani A. Commentary on “A New Onset of Mania in a 49-Year-Old Man: An Interesting Case of Wilson Disease”. Journal Of Psychiatric Practice 2020, 26: 510-517. PMID: 33275389, DOI: 10.1097/pra.0000000000000507.Commentaries, Editorials and LettersConceptsPrimary psychiatric disordersYears of ageWilson's diseasePsychiatric disordersNew onsetDiagnostic workupAcute cognitive declineFormal psychiatric historyCommon clinical manifestationsNeurological side effectsFurther diagnostic workupLow serum ceruloplasminMagnetic resonance imagingSecondary maniaAtypical presentationClinical manifestationsHepatic abnormalitiesPsychiatric providersPatient presentationMetabolism disordersBrain abnormalitiesPsychiatric symptomsTreatment considerationsCorrect diagnosisPsychiatric historyChronic Pain, Mood Disorders and Substance Use: Outcomes of Interdisciplinary Care in a Residential Psychiatric Hospital
Buono FD, Savage SR, Cerrito B, O’Connell J, Garakani A, Ackerman S, Cutter CJ. Chronic Pain, Mood Disorders and Substance Use: Outcomes of Interdisciplinary Care in a Residential Psychiatric Hospital. Journal Of Pain Research 2020, 13: 1515-1523. PMID: 32612379, PMCID: PMC7322115, DOI: 10.2147/jpr.s250568.Peer-Reviewed Original ResearchPain severityPsychiatric hospitalChronic Pain Coping InventoryChronic pain programRetrospective chart reviewOpioid use disorderPain Coping InventorySpecific psychiatric disordersCo-occurring disordersPsycho-behavioral therapySignificant differencesPain reliefChart reviewAnalgesic opioidsPain programChronic painPain interferenceInterdisciplinary careMedication managementMood disordersPain copingPsychiatric disordersUse disordersOpioidsPatients
2013
Transient Febrile Reaction After Electroconvulsive Therapy (ECT) in a Young Adult With Intellectual Disability and Bipolar Disorder
Majeske MF, Garakani A, Maloutas E, Bryson EO, Kellner CH. Transient Febrile Reaction After Electroconvulsive Therapy (ECT) in a Young Adult With Intellectual Disability and Bipolar Disorder. Journal Of Ect 2013, 29: e63-e65. PMID: 23774055, DOI: 10.1097/yct.0b013e3182972b8c.Peer-Reviewed Case Reports and Technical NotesConceptsElectroconvulsive therapyECT treatmentManic symptomsIntellectual disabilityBipolar disorderUse of ECTAdditional ECT treatmentsMultiple medication trialsTransient febrile reactionMild-moderate intellectual disabilityFever workupTransient feverMedication trialsFebrile reactionsPressured speechManic statePatient's motherPsychiatric disordersPatientsYoung adultsDisordersFeverTreatmentTherapySymptoms
2010
Potential Psychiatric Applications of Metabotropic Glutamate Receptor Agonists and Antagonists
Krystal JH, Mathew SJ, D’Souza D, Garakani A, Gunduz-Bruce H, Charney DS. Potential Psychiatric Applications of Metabotropic Glutamate Receptor Agonists and Antagonists. CNS Drugs 2010, 24: 669-693. PMID: 20658799, DOI: 10.2165/11533230-000000000-00000.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsPreliminary clinical trialsPositive allosteric modulatorsPsychiatric disordersClinical trialsAnimal modelsAllosteric modulatorsGroup II mGluR agonistGroup IMetabotropic glutamate receptor agonistAnxiety disordersPotential psychiatric applicationsGlutamate receptor agonistsMetabotropic glutamate receptorsTreatment of schizophreniaRole of glutamateForm of depressionMGluR agonistAntidepressant propertiesMGluR5 agonistReceptor agonistGlutamate receptorsMood disordersArea of schizophreniaPromising agentAgonists